South Korea · Delayed Price · Currency is KRW GC Biopharma Statistics
Total Valuation
GC Biopharma has a market cap or net worth of KRW 1.45 trillion. The enterprise value is 2.40 trillion.
| Market Cap | 1.45T |
| Enterprise Value | 2.40T |
Important Dates
The last earnings date was Friday, May 29, 2026.
| Earnings Date | May 29, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
GC Biopharma has 11.41 million shares outstanding. The number of shares has increased by 0.00% in one year.
| Current Share Class | 11.41M |
| Shares Outstanding | 11.41M |
| Shares Change (YoY) | +0.00% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | 0.94% |
| Owned by Institutions (%) | 14.60% |
| Float | 5.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 16.36 |
| PS Ratio | 0.71 |
| PB Ratio | 1.11 |
| P/TBV Ratio | 1.61 |
| P/FCF Ratio | 22.02 |
| P/OCF Ratio | 8.99 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.15, with an EV/FCF ratio of 36.50.
| EV / Earnings | -172.73 |
| EV / Sales | 1.17 |
| EV / EBITDA | 10.15 |
| EV / EBIT | 16.19 |
| EV / FCF | 36.50 |
Financial Position
The company has a current ratio of 1.25, with a Debt / Equity ratio of 0.70.
| Current Ratio | 1.25 |
| Quick Ratio | 0.40 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | 5.72 |
| Debt / FCF | 13.90 |
| Interest Coverage | 1.38 |
Financial Efficiency
Return on equity (ROE) is -2.29% and return on invested capital (ROIC) is 3.18%.
| Return on Equity (ROE) | -2.29% |
| Return on Assets (ROA) | 1.55% |
| Return on Invested Capital (ROIC) | 3.18% |
| Return on Capital Employed (ROCE) | 4.12% |
| Weighted Average Cost of Capital (WACC) | 6.82% |
| Revenue Per Employee | 1.00B |
| Profits Per Employee | -6.80M |
| Employee Count | 2,042 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 1.71 |
Taxes
In the past 12 months, GC Biopharma has paid 8.37 billion in taxes.
| Income Tax | 8.37B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.25% in the last 52 weeks. The beta is 0.73, so GC Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | -1.25% |
| 50-Day Moving Average | 140,874.00 |
| 200-Day Moving Average | 144,057.00 |
| Relative Strength Index (RSI) | 37.85 |
| Average Volume (20 Days) | 90,460 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GC Biopharma had revenue of KRW 2.04 trillion and -13.90 billion in losses. Loss per share was -1,218.00.
| Revenue | 2.04T |
| Gross Profit | 562.64B |
| Operating Income | 71.58B |
| Pretax Income | -23.45B |
| Net Income | -13.90B |
| EBITDA | 159.74B |
| EBIT | 71.58B |
| Loss Per Share | -1,218.00 |
Balance Sheet
The company has 42.73 billion in cash and 914.33 billion in debt, with a net cash position of -871.60 billion or -76,368.16 per share.
| Cash & Cash Equivalents | 42.73B |
| Total Debt | 914.33B |
| Net Cash | -871.60B |
| Net Cash Per Share | -76,368.16 |
| Equity (Book Value) | 1.31T |
| Book Value Per Share | 107,663.35 |
| Working Capital | 258.26B |
Cash Flow
In the last 12 months, operating cash flow was 161.14 billion and capital expenditures -95.38 billion, giving a free cash flow of 65.76 billion.
| Operating Cash Flow | 161.14B |
| Capital Expenditures | -95.38B |
| Depreciation & Amortization | 88.15B |
| Net Borrowing | -66.57B |
| Free Cash Flow | 65.76B |
| FCF Per Share | 5,761.96 |
Margins
Gross margin is 27.54%, with operating and profit margins of 3.50% and -0.68%.
| Gross Margin | 27.54% |
| Operating Margin | 3.50% |
| Pretax Margin | -1.15% |
| Profit Margin | -0.68% |
| EBITDA Margin | 7.82% |
| EBIT Margin | 3.50% |
| FCF Margin | 3.22% |
Dividends & Yields
This stock pays an annual dividend of 1,500.00, which amounts to a dividend yield of 1.18%.
| Dividend Per Share | 1,500.00 |
| Dividend Yield | 1.18% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.00% |
| Shareholder Yield | 1.18% |
| Earnings Yield | -0.96% |
| FCF Yield | 4.54% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for GC Biopharma is 209,400.00, which is 74.79% higher than the current price. The consensus rating is "Buy".
| Price Target | 209,400.00 |
| Price Target Difference | 74.79% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 4.85% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on June 7, 2013. It was a forward split with a ratio of 1.05.
| Last Split Date | Jun 7, 2013 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
GC Biopharma has an Altman Z-Score of 1.99 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.99 |
| Piotroski F-Score | 5 |